Major insurers are now seeking smaller, single-digit premium increases for Affordable Care Act (ACA) plans; drug makers and distributors of painkillers being sued for their alleged role in the opioid crisis are trying to build goodwill by giving grants and donations to hard-hit counties, cities, and states that are filing the lawsuits; hundreds of people have sued Bristol-Myers Squibb and Otsuka, alleging that the drug Abilify caused compulsive behavior.
The Affordable Care Act (ACA) marketplace may finally be stabilizing. For years, insurers have made large hikes to premiums for ACA plans, but major insurers are now seeking smaller single-digit increases, according to The Wall Street Journal. Some big insurers in Texas, Illinois, Arizona, and North Carolina are even seeking reductions. However, there are still plans that will see large increases to reflect the health of the members they are serving.
Communities across the country are filing lawsuits against drug makers and distributors of painkillers for their alleged role in the ongoing opioid epidemic. Now, these same companies are giving grants and donations to those very same communities, cities, and states. Bloomberg reported that the companies are not only trying to build goodwill ahead of potential settlements, but the charity could help them reduce their tax bills. For the areas hit by the opioid epidemic, the money is going to things like prevention programs.
Hundreds of people have sued Bristol-Myers Squibb and Otsuka, alleging that their drug aripiprazole (Abilify) caused compulsive behavior. The lawsuits claim the drug, an antipsychotic, caused them to gamble, eat, or have sex compulsively, reported STAT. The exact reason why the drug causes such behavior in a handful of the millions of people who take the drug has not been discovered yet. The FDA issued a safety warning in 2016 acknowledging that some patients have reported these uncontrollable urges. Abilify was first approved to treat schizophrenia and has since been approved to treat bipolar disorder, irritability associated with autistic disorder, Tourette syndrome, and major depressive disorder.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
2 Commerce Drive
Cranbury, NJ 08512